Oncology Patient Advocacy Spotlight
This week in health care trends, our oncology patient advocacy spotlight includes an in-depth pool of evidence for supportive and palliative care, a study of palliative care in clinical trials, and a new gene that is strongly linked to breast cancer.
The articles below are from our dedicated Oncology Patient Advocacy e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check our e-magazine frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
This detailed resource from the University of Maryland lays out in-depth research and information helpful to supportive and palliative care professionals. For each type of cancer, the guide provides “descriptions of the pathophysiology and treatment of common physical and psychosocial complications of cancer and its treatment, including complications such as pain, anxiety, depression, fatigue, and nausea and vomiting.”
Implementation of Supportive Care and Best Supportive Care Interventions in Clinical Trials Enrolling Patients with Cancer
This literature review, published in the Annals of Oncology, examines “how supportive care (SC) and best supportive care (BSC) are implemented in clinical trials when used as a comparison treatment arm.” Their findings? “The implementation of SC in clinical trials in this systematic review is highly variable. The vast majority of the studies did not meet the WHO guidelines on SC because palliative care therapies were not recommended or integrated into care.”
We already know that 5-10% of breast cancer cases are related to genetics, and we already know to do BRCA testing. But a recent study out of the University of Toronto has identified another gene, RECQL, and argues that “50% of women with RECQL mutation will develop breast cancer.”